What is the appropriate insomnia treatment and dosing for an 88‑year‑old woman?

Treatment Recommendation for Insomnia in an 88-Year-Old Woman

For an 88-year-old woman with insomnia, start with cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, and if pharmacotherapy is needed, use low-dose doxepin 3 mg or eszopiclone 1-2 mg at the lowest effective dose for the shortest duration possible. 1, 2

Treatment Algorithm

First-Line: Non-Pharmacologic Approach

CBT-I is superior to medications for long-term insomnia management in older adults and should be the initial treatment. 2, 3 The evidence shows CBT-I provides equivalent short-term results (2-4 weeks) to pharmacotherapy but demonstrates superior long-term outcomes with fewer adverse effects 2. This is particularly critical at age 88 given the heightened risks of falls, cognitive impairment, and drug interactions.

CBT-I components to implement:

• Sleep restriction therapy (limiting time in bed to actual sleep time)
• Stimulus control (bed only for sleep/sex, leave bedroom if unable to sleep within 15-20 minutes)
• Sleep hygiene education (stable bed/wake times, avoid daytime napping after 2 PM or limit to 30 minutes, avoid caffeine/nicotine/alcohol)
• Relaxation techniques (progressive muscle relaxation, guided imagery, diaphragmatic breathing) 1

Important caveat: Sleep hygiene education alone is ineffective and potentially harmful if it delays referral for effective behavioral treatments like CBT-I 2.

Second-Line: Pharmacotherapy (When CBT-I Unavailable or Insufficient)

All medications must be started at the lowest available dose given increased sensitivity to peak drug effects and reduced clearance in older adults 1.

Preferred Medication Options:

For sleep-onset insomnia:

• Low-dose doxepin 3 mg at bedtime 2, 4
  • Demonstrated efficacy in older adults with improved ISI scores at week 4
  • No statistically significant difference in adverse events versus placebo in trials
  • Lacks the anticholinergic burden of higher antidepressant doses
  • Note: Suicide risk with low-dose doxepin as hypnotic is unknown and cannot be excluded 2

For sleep-maintenance insomnia:

• Eszopiclone 2 mg at bedtime 5, 4
• Low-dose doxepin 3-6 mg 2, 4

For both sleep-onset and maintenance:

• Eszopiclone 1-2 mg (start at 1 mg for difficulty falling asleep, 2 mg for difficulty maintaining sleep) 5, 4
  • Established safety and efficacy in two 2-week and one 12-week trials in elderly patients
  • Reduced sleep latency, increased sleep maintenance, decreased daytime napping
  • Improved quality of life measures including mood, physical health, and vitality 5

Alternative option:

• Prolonged-release melatonin - high safety profile appropriate for this age group 6

Medications to AVOID:

Benzodiazepines should NOT be used 2, 3, 4. The harms substantially outweigh benefits:

• Risk for dependency and diversion
• Falls and cognitive impairment in older patients
• Hypoventilation in patients with respiratory conditions
• Neuromuscular complications 2

Trazodone should be avoided despite being frequently prescribed off-label 1, 4. There is no systematic evidence for effectiveness, and the NIH concluded that risks outweigh benefits 1. While it may improve sleep quality and continuity, it carries significant risks in the elderly 4.

Antihistamines, antipsychotics, and anticonvulsants - no systematic evidence for effectiveness, with risks outweighing benefits 1.

Combination Therapy Consideration

Combining CBT-I with pharmacotherapy may provide better short-term outcomes than either alone, with medications providing immediate relief and behavioral therapy providing sustained long-term benefit 1. However, the 2026 AASM guideline suggests against combination treatment versus CBT-I alone (conditional recommendation), unless the patient highly values early total sleep time improvement over reducing daytime symptoms 7.

Critical Safety Considerations at Age 88

• Pharmacokinetic changes: Reduced drug clearance increases exposure and adverse event risk 1
• Pharmacodynamic changes: Increased sensitivity to peak drug effects 1
• Falls risk: Dose and time-dependent impairment is a major concern 1
• Polypharmacy: Check for CYP3A4 interactions with eszopiclone; dose adjustment may be needed 5
• FDA warning: Nonbenzodiazepine BZRAs carry risk for serious injuries from sleep behaviors (sleepwalking, sleep driving) 2

Duration and Monitoring

• Use pharmacotherapy for the shortest possible duration 2, 4
• Counsel all patients on potential risks before initiating medication 2
• Monitor for adverse effects, particularly cognitive impairment, falls, and daytime somnolence
• Reassess regularly and attempt to taper medications while maintaining behavioral interventions

The key principle: behavioral therapy provides better sustained outcomes over time, while medications offer only short-term relief with significant age-related risks 1, 2.